Guardant Health, Inc., was incorporated in Delaware in December 2011. The company is a leading precision oncology company dedicated to helping the world conquer cancer through the use of its proprietary blood tests, extensive datasets and advanced analysis. They revolutionize patient care by providing key insights into disease drivers using advanced blood and tissue testing, real-world data, and artificial intelligence analysis. Their tests help improve treatment outcomes at all stages, including early cancer screening, early cancer recurrence monitoring, and treatment option selection for patients with advanced cancer. 

Expected P&L on Expiry

Key Stats

Pricing Model

About GH20260417C100